Resmed Inc ( (RMD) ) has released its Q3 earnings. Here is a breakdown of the information Resmed Inc presented to its investors.
Resmed Inc., a leader in digital health technologies and cloud-connected medical devices, has reported its financial results for the third quarter of fiscal year 2025. The company specializes in treating sleep apnea, COPD, and other chronic diseases, offering solutions that improve patient care and reduce healthcare costs globally.
In the latest earnings report, Resmed Inc. announced an 8% year-over-year revenue growth, reaching $1.3 billion, with operating profit increasing by 14%. The company’s gross margin improved by 140 basis points to 59.3%, and diluted earnings per share rose to $2.48. The company also reported a strong operating cash flow of $579 million.
Key financial highlights include a 9% revenue growth on a constant currency basis, driven by increased demand for sleep devices and masks, as well as growth in the Residential Care Software business. The company’s net income increased by 21%, and non-GAAP net income rose by 11%. Resmed’s strategic initiatives, such as the launch of the NightOwl home sleep apnea test and a comprehensive brand evolution, underscore its commitment to innovation and market leadership.
Resmed’s management remains optimistic about the future, focusing on expanding its market presence and addressing the needs of over 2.3 billion people with sleep and breathing health issues. The company aims to continue its growth trajectory by enhancing patient access to its products and solutions, thereby improving global health outcomes.